Propafenone Hydrochloride
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB01182 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 27 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | manic bipolar affective disorder | KG + DL |
| 2 | catecholaminergic polymorphic ventricular tachycardia | KG + DL |
| 3 | periodic paralysis with transient compartment-like syndrome | KG + DL |
| 4 | Prinzmetal angina | KG + DL |
| 5 | incessant infant ventricular tachycardia | KG + DL |
| 6 | arrhythmogenic right ventricular cardiomyopathy | KG + DL |
| 7 | nephrogenic syndrome of inappropriate antidiuresis | KG + DL |
| 8 | trichotillomania | KG + DL |
| 9 | Tourette syndrome | KG + DL |
| 10 | hyperthyroidism | KG + DL |
| 11 | genetic cardiac rhythm disease | KG + DL |
| 12 | obsolete susceptibility to ischemic stroke | KG + DL |
| 13 | Graves disease | KG + DL |
| 14 | resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta | KG + DL |
| 15 | neonatal thyrotoxicosis | KG + DL |
| 16 | sick sinus syndrome 2, autosomal dominant | KG + DL |
| 17 | sudden cardiac arrest | KG + DL |
| 18 | thyrotoxicosis | KG + DL |
| 19 | ventricular fibrillation, paroxysmal familial | KG + DL |
| 20 | ABri amyloidosis | KG + DL |
| 21 | sarcoglycanopathy | KG + DL |
| 22 | Wildervanck syndrome | KG + DL |
| 23 | hyperthyroxinemia | KG + DL |
| 24 | nephrogenic diabetes insipidus | KG + DL |
| 25 | brain stem infarction | KG + DL |
| 26 | autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome | KG + DL |
| 27 | autoimmune thyroid disease | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.